- On news that the company has introduced eight cancer products, Enzo Diagnostics in the USA saw its shares soar on heavy volume last week. The company is a unit of the US biotechnology concern Enzo Biochem. The eight products are additions to the Enzo group's line of monoclonal antibodies that are used in cancer research. Seven of the products will be used to assist in the identification of metastatic cancers and the eighth product is a staining kit for detecting 18 of the MAbs the company markets for research purposes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze